Jacob Miller has spent his career focused on one of the biggest challenges in regenerative medicine: moving promising science out of the laboratory and into patients. His experience spans regenerative medicine, biotechnology, regulatory strategy, clinical research, and commercialization.
He has worked on bioreactor development and bioengineered therapeutics at Harvard Apparatus Regenerative Technology, supported biotechnology and pharmaceutical companies at Complya, conducted oncology clinical research at Hartford HealthCare, and contributed to healthcare quality initiatives at Yale's Center for Outcomes Research and Evaluation. Most recently, Jacob led cell therapy and technology commercialization programs at the Advanced Regenerative Manufacturing Institute (ARMI), working across a national network of academic and industry partners.
At Hopewell, Jacob advises the team on navigating the regenerative medicine ecosystem, developing translational strategies, and building the partnerships needed to help move regenerative technologies toward meaningful patient impact. He holds an MS in Molecular & Cell Biology with a concentration in Genetics from the University of Connecticut and a BA in Chemistry from the College of the Holy Cross.
